Custom Site Search

Tuesday, August 10, 2010

The march of the generics!

For those wishing to know, there are many medications slated to lose patent life in the next several months. One caveat: once the patent expires, there is often litigation which results in a prolongation of the legal life of the brand. There are several events that may occur that prolong brand exposure, including litigation, patent settlements (manufacturers will agree to discontinue litigation in exchange for some monetary reward--nice, huh), final FDA approval, submissions of citizen petitions on behalf of brand manufacturers to the FDA, and "at risk launches" which means that once a generic is approved the generic manufacturer can go ahead with the generic but risks further litigation with the brand manufacturer.

That being said here's a list of some drugs going off patent:
Skelid
Cardene SR
Iopidine eye drops
Vistide
Combigan eye drops
Androgel
Androderm
Arixtra
Carbatrol
Concerta
Duac
Lovenox
Lybrel
metadate CD
Sanctura
Tarka
Elestat eye drops

No comments: